<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Predictors and treatment of isolated recurrence in vulvar cancer confined to the vulva or perineum

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

Organization Authors

Co-Authors

Güngördük, Kemal

Demirkıran, Fuat

Khatib, Ghanim

Öz, Murat

Gülseren, Varol

Minareci, Yaǧmur

Sancı, Muzaffer

Şahin, Hanifi

Tosun, Özgür

Taşkın, Salih

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Aim: This study evaluated predictors and treatment of isolated vulvar recurrence (IVR) in patients with stage I–II tumors locally confined to the vulva. Methods: We retrospectively collected data from patients with stage I–II vulvar squamous cell carcinoma (VSCC) who underwent surgery for vulvar cancer between 2005 and 2021. The IVR group comprised patients with stage I–II tumors at the time of initial diagnosis who developed recurrence confined to the vulvar region after initial treatment. Results: This study included 416 patients with early-stage (stage I–II) VSCC. IVR was developed in 67 (16.1%) patients; the remaining 349 patients were included in the control group. Independent predictors of IVR were depth of invasion, perineural invasion, and positive surgical margins. Among patients with tumors confined to the vulva at the time of initial diagnosis, the 5-year overall survival rates were 59.0% and 87.0% in the IVR and control groups, respectively (P < 0.001). In the IVR group, the cumulative rates of local relapse were 38.8% in the first year, 58.2% in the second year, and 74.6% in the third year. Conclusion: Independent predictors of IVR in early-stage VSCC were depth of invasion, perineural invasion, and positive surgical margins. Approximately two-thirds of local recurrences occurred in the first 3 years after treatment.

Source

Publisher

Wolters Kluwer Medknow Publications

Subject

Citation

item.page.haspartof

Source

Journal of Cancer Research and Therapeutics

item.page.ispartofseries

item.page.edition

DOI

10.4103/jcrt.jcrt_1698_24

item.page.datauri

item.page.link

Rights

CC BY-NC-SA (Attribution-NonCommercial-ShareAlike)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY-NC-SA (Attribution-NonCommercial-ShareAlike)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
0
Görüntülenme
8
İndirme
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators